{"id":450489,"date":"2021-03-04T07:33:07","date_gmt":"2021-03-04T12:33:07","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=450489"},"modified":"2021-03-04T07:33:07","modified_gmt":"2021-03-04T12:33:07","slug":"arbutus-reports-fourth-quarter-and-year-end-2020-financial-results-and-provides-corporate-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/arbutus-reports-fourth-quarter-and-year-end-2020-financial-results-and-provides-corporate-update\/","title":{"rendered":"Arbutus Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Update"},"content":{"rendered":"
\n

\n AB-729, Arbutus\u2019 proprietary subcutaneously delivered RNAi agent, demonstrates<\/strong>
\n robust and continuous declines in hepatitis B surface antigen (HBsAg) in subjects with chronic hepatitis B (HBV) with favorable safety and tolerability data <\/strong>\n <\/p>\n

\n Reductions in <\/strong>
\n HBsAg<\/strong>
\n seen in both HBV DNA negative and HBV DNA positive subjects support a potential dosing schedule for AB-729 as infrequently as every 8 to 12 weeks<\/strong>\n <\/p>\n

\n Several AB-729 Phase 2 proof-of-concept combination clinical trials expected to initiate this year<\/strong>\n <\/p>\n

\n AB-836, Arbutus\u2019 proprietary oral capsid inhibitor, on track to begin a Phase 1a\/1b clinical trial in healthy volunteers and subjects with HBV in the first half of 2021 <\/strong>\n <\/p>\n

\n Conference Call and Webcast Scheduled Today at 8:45 AM ET<\/strong>\n <\/p>\n

WARMINSTER, Pa., March 04, 2021 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today reports its fourth quarter and year-end 2020 financial results and provides a corporate update.<\/p>\n

William Collier, President and Chief Executive Officer of Arbutus, stated, \u201cOur current data set for AB-729, our lead compound in development for HBV, has grown substantially over the past 12 months and increases our confidence that it has the potential to be a cornerstone drug in future HBV combination regimens.\u201d<\/p>\n

Mr. Collier added, \u201cLooking ahead, 2021 is expected to provide us with important insights regarding the potential therapeutic value of several compounds in our proprietary HBV pipeline including: longer term Phase 1a\/1b dosing results for AB-729; the initiation of a Phase 2 combination clinical trial with AB-729 and Assembly Biosciences\u2019 lead core inhibitor; initiation of Phase 2 clinical trials for AB-729 and one or more approved or investigational agents; and initial Phase 1a\/1b data from our proprietary oral capsid inhibitor, AB-836.\u201d<\/p>\n

Dr. Gaston Picchio, Chief Development Officer of Arbutus, commented, \u201cAB-729 has shown impressive reductions in HBsAg with an unremarkable longer term safety profile in the clinical data from our Phase 1a\/1b clinical trial. The data that has emerged from this clinical trial so far is encouraging and it suggests that AB-729 could potentially be dosed less frequently than every 4 weeks potentially providing a competitive advantage. As a matter of fact, we are testing a dosing schedule of every 8 weeks in our Phase 2 clinical trial in collaboration with Assembly.\u201d<\/p>\n

Dr. Picchio added, \u201cWe are pleased that we have initiated screening for our proof-of-concept Phase 2 clinical trial combining AB-729 with Assembly Biosciences\u2019 lead core inhibitor candidate, also known as a capsid inhibitor, vebicorvir, and a nucleos(t)ide reverse transcriptase inhibitor.\u201d<\/p>\n

\n
\n Pipeline Update<\/u>
\n <\/strong>\n <\/p>\n

\n AB-729<\/strong>\n <\/p>\n